{
    "id": "college_biology-097",
    "question": "Antibiotics that affect bacterial cells interfere with all of the following EXCEPT",
    "options": {
        "A": "peptidoglycan synthesis",
        "B": "protein synthesis",
        "C": "DNA synthesis",
        "D": "reverse transcriptase"
    },
    "answer": "D",
    "predict": "{\"step_by_step_thinking\": \"To answer this question, we need to consider the mechanisms by which antibiotics affect bacterial cells. The options provided are peptidoglycan synthesis, protein synthesis, DNA synthesis, and reverse transcriptase. Antibiotics can affect bacterial cells in various ways, but the question asks for the process that antibiotics do NOT interfere with. Let's examine each option: Antibiotics can affect bacterial cells by interfering with: - Peptidoglycan synthesis: Antibiotics like penicillin and vancomycin inhibit peptidoglycan synthesis, which is essential for bacterial cell wall formation. This is correct, so option A is not the answer. - Protein synthesis: Antibiotics like tetracycline, erythromycin, and chloramphenicol inhibit protein synthesis by binding to bacterial ribosomes. This is correct, so option B is not the answer. - DNA synthesis: Some antibiotics, such as the antifungals fluconazole and griseofulvin, can inhibit DNA synthesis. This is correct, so option C is not the answer. - Reverse transcriptase: Reverse transcriptase is an enzyme involved in the replication of retroviruses, not bacteria. Antibiotics do not target reverse transcriptase. This is the correct answer because antibiotics do not interfere with reverse transcriptase. Therefore, the correct answer is D. reverse transcriptase.\", \"answer_choice\": \"D\"}",
    "snippets": [
        {
            "id": "Cell_Biology_Alberts_1668",
            "title": "Cell_Biology_Alberts",
            "content": "Many of the most effective antibiotics used in modern medicine are compounds made by fungi that inhibit bacterial protein synthesis. Fungi and bacteria compete for many of the same environmental niches, and millions of years of coevolution have resulted in fungi producing potent bacterial inhibitors. Some of these drugs exploit the structural and functional differences between bacterial and eukaryotic ribosomes so as to interfere preferentially with the function of bacterial ribosomes. Thus, humans can take high dosages of some of these compounds without undue toxicity. Many antibiotics lodge in pockets in the ribosomal RNAs and simply interfere with the smooth operation of the ribosome; others block specific parts of the ribosome such as the exit channel (Figure 6\u201375). Table 6\u20134 lists some common antibiotics of this kind along with several other inhibitors of protein synthesis, some of which act on eukaryotic cells and therefore cannot be used as antibiotics."
        },
        {
            "id": "Cell_Biology_Alberts_6504",
            "title": "Cell_Biology_Alberts",
            "content": "Figure 23\u201333 antibiotic targets. Although there are many antibiotics in clinical use, they have a narrow range of targets, which are highlighted in yellow. A few representative antibiotics in each class are listed. Nearly all antibiotics used to treat human infections fall into one of these categories. The vast majority inhibit either bacterial protein synthesis or bacterial cell wall synthesis."
        },
        {
            "id": "Pharmacology_Katzung_5957",
            "title": "Pharmacology_Katzung",
            "content": "Screening of microbial products led to the discovery of a number of growth-inhibiting compounds that have proved to be clinically useful in cancer chemotherapy. Many of these antibiotics bind to DNA through intercalation between specific bases and block the synthesis of RNA, DNA, or both; cause DNA strand scission; and interfere with cell replication. All of the anti-cancer antibiotics now being used in clinical practice are products of various strains of the soil microbe Streptomyces. These include the anthracyclines, bleomycin, and mitomycin."
        },
        {
            "id": "Cell_Biology_Alberts_6505",
            "title": "Cell_Biology_Alberts",
            "content": "Figure 23\u201334 Three general mechanisms of antibiotic resistance. (A) A nonresistant wild-type bacterial cell bathed in a drug (red triangles) that binds to and inhibits an essential enzyme (light green) will be killed due to enzyme inhibition. (B) A bacterium that has altered the drug\u2019s target enzyme so that the drug no longer binds to the enzyme will survive and proliferate. In many cases, a single point mutation in the gene encoding the target protein can generate resistance. (C) A bacterium that expresses an enzyme (dark green) that either degrades or covalently modifies the drug will survive and proliferate. Some resistant bacteria, for example, make \u03b2-lactamase enzymes, which cleave penicillin and similar molecules. (D) A bacterium that expresses or up-regulates an efflux pump that ejects the drug from the bacterial cytoplasm (using energy derived from either ATP hydrolysis or the electrochemical gradient across the bacterial plasma membrane) will survive and proliferate. Some"
        },
        {
            "id": "Cell_Biology_Alberts_6495",
            "title": "Cell_Biology_Alberts",
            "content": "1292 Chapter 23: Pathogens and Infection H2N2 H3N? used to treat infections in humans, just in time to prevent tens of thousands of deaths from infected battlefield wounds in World War II. Because bacteria (see Figure 1\u201317) are not closely related evolutionarily to the eukaryotes they infect, much of their basic machinery for DNA replication and transcription, RNA translation, and metabolism differs from that of their host. These differences enable us to develop antibacterial drugs that exhibit selective toxicity, in that they specifically inhibit these processes in bacteria without disrupting them in the host. Most of the antibiotics that we use to treat bacterial infections are small molecules that inhibit macromolecular synthesis in bacteria by targeting bacterial enzymes that either are distinct from their eukaryotic counterparts or are involved in pathways such as cell wall biosynthesis that are absent in animals (Figure 23\u201333 and see Table 6\u20134)."
        },
        {
            "id": "Cell_Biology_Alberts_6497",
            "title": "Cell_Biology_Alberts",
            "content": "Once a pathogen has chanced upon an effective drug-resistance strategy, the newly acquired or mutated genes that confer the resistance are frequently spread throughout the pathogen population by horizontal gene transfer. They may even spread between pathogens of different species. The highly effective but expensive antibiotic vancomycin, for example, is used as a treatment of last resort for many severe, hospital-acquired, Gram-positive bacterial infections that are resistant to most other known antibiotics. Vancomycin prevents one step in bacterial cell wall synthesis\u2014the cross-linking of peptidoglycan chains in the bacterial cell wall (see Figure 23\u20133B). Resistance can arise if the bacterium synthesizes a cell wall using different subunits that do not bind vancomycin. The most effective form of vancomycin resistance depends on the acquisition of a transposon (see Figure 5\u201360) containing seven genes, the products of which work together to sense the"
        },
        {
            "id": "Cell_Biology_Alberts_6501",
            "title": "Cell_Biology_Alberts",
            "content": "Drug-resistance genes acquired by horizontal transfer frequently come from environmental microbial reservoirs. Nearly all antibiotics used to treat bacterial infections today are based on natural products produced by fungi or bacteria. Penicillin, for example, is made by the mold Penicillium, and more than 50% of the antibiotics currently used in the clinic are made by Gram-positive bacteria of the genus Streptomyces, which reside in the soil. It is believed that microorganisms produce antimicrobial compounds, many of which have probably existed on Earth for hundreds of millions of years, as weapons in their competition with other microorganisms in the environment. Surveys of bacteria taken from soil samples that have never been exposed to antibiotic drugs used in modern medicine reveal that the bacteria are typically already resistant to about seven or eight of the antibiotics widely used in clinical practice. When pathogenic microorganisms are faced with the selective pressure"
        },
        {
            "id": "Cell_Biology_Alberts_6503",
            "title": "Cell_Biology_Alberts",
            "content": "Like most other aspects of infectious disease, human behavior has exacerbated the problem of drug resistance. Many patients take antibiotics for symptoms that are typically caused by viruses (flu-like illnesses, colds, sore throats, and earaches) and these drugs have no effects. Persistent and chronic misuse of antibiotics can eventually result in antibiotic-resistant normal flora, which can then transfer the resistance to pathogens. Antibiotics are also misused in agriculture, where they are commonly employed as food additives to promote the growth and health of farm animals. An antibiotic closely related to vancomycin was commonly added to cattle feed in Europe; the resulting resistance in the normal flora of these animals is widely believed to be one of the original sources for vancomycin-resistant bacteria that now threaten the lives of hospitalized patients."
        },
        {
            "id": "Cell_Biology_Alberts_6493",
            "title": "Cell_Biology_Alberts",
            "content": "The development of drugs that cure rather than prevent infections has had a major impact on human health. Antibiotics, which are either bactericidal (they kill bacteria) or bacteriostatic (they inhibit bacterial growth without killing), are the most successful class of such drugs. Penicillin was one of the first antibiotics = jumps from monkey and ape to human"
        },
        {
            "id": "First_Aid_Step1_201",
            "title": "First_Aid_Step1",
            "content": "mecHaNism oF resistaNce Occurs in bacteria (eg, Enterococcus) via amino acid modification of D-Ala-D-Ala to D-Ala-D-Lac. \u201cIf you Lack a D-Ala (dollar), you can\u2019t ride the van (vancomycin).\u201d Specifically target smaller bacterial ribosome (70S, made of 30S and 50S subunits), leaving human ribosome (80S) unaffected. All are bacteriostatic, except aminoglycosides (bactericidal) and linezolid (variable). Chloramphenicol, Clindamycin Erythromycin (macrolides) Linezolid \u201cBuy AT 30, CCEL (sell) at 50.\u201d cliNical Use Severe gram \u229d rod infections. Synergistic with \u03b2-lactam antibiotics. Neomycin for bowel surgery. aDVerse eFFects Nephrotoxicity, Neuromuscular blockade (absolute contraindication with myasthenia gravis), Ototoxicity (especially with loop diuretics), Teratogenicity. mecHaNism oF resistaNce Bacterial transferase enzymes inactivate the drug by acetylation, phosphorylation, or adenylation. Tetracyclines Tetracycline, doxycycline, minocycline."
        },
        {
            "id": "Cell_Biology_Alberts_1339",
            "title": "Cell_Biology_Alberts",
            "content": "DNA-only transposons, so named because they exist only as DNA during their movement, predominate in bacteria, and they are largely responsible for the spread of antibiotic resistance in bacterial strains. When antibiotics like penicillin and streptomycin first became widely available in the 1950s, most bacteria that caused human disease were susceptible to them. Now, the situation is different\u2014 antibiotics such as penicillin (and its modern derivatives) are no longer effective against many modern bacterial strains, including those causing gonorrhea and bacterial pneumonia. The spread of antibiotic resistance is due largely to genes that encode antibiotic-inactivating enzymes that are carried on transposons (Figure 5\u201360). Although these mobile elements can transpose only within cells that already carry them, they can be moved from one cell to another through other mechanisms known collectively as horizontal gene transfer (see Figure 1\u201319). Once introduced into a new cell, a transposon"
        },
        {
            "id": "Pharmacology_Katzung_4948",
            "title": "Pharmacology_Katzung",
            "content": "with a nearby peptide. Cross-links give the cell wall its rigidity. Beta-lactam antibiotics, structural analogs of the natural d-Ala-d-Ala substrate, covalently bind to the active site of PBPs. This binding inhibits the transpeptidation reaction (Figure 43\u20135) and halts peptidoglycan synthesis, and the cell dies. The exact mechanism of cell death is not completely understood, but autolysins are involved in addition to the disruption of cross linking of the cell wall. Beta-lactam antibiotics kill bacterial cells only when they are actively growing and synthesizing cell wall."
        },
        {
            "id": "Pharmacology_Katzung_4947",
            "title": "Pharmacology_Katzung",
            "content": "Penicillins, like all \u03b2-lactam antibiotics, inhibit bacterial growth by interfering with the transpeptidation reaction of bacterial cell wall synthesis. The cell wall is a rigid outer layer that completely surrounds the cytoplasmic membrane (Figure 43\u20133), maintains cell integrity, and prevents cell lysis from high osmotic pressure. The cell wall is composed of a complex, cross-linked polymer of polysaccharides and peptides known as peptidoglycan. The polysaccharide contains alternating amino sugars, N-acetylglucosamine and N-acetylmuramic acid (Figure 43\u20134). A five-amino-acid peptide is linked to the N-acetylmuramic acid sugar. This peptide terminates in d-alanyl-d-alanine. Penicillin-binding protein (PBP, an enzyme) removes the terminal alanine in the process of forming a cross-link with a nearby peptide. Cross-links give the cell wall its rigidity. Beta-lactam antibiotics, structural analogs of the natural d-Ala-d-Ala substrate, covalently bind to the active site of PBPs. This"
        },
        {
            "id": "Cell_Biology_Alberts_6500",
            "title": "Cell_Biology_Alberts",
            "content": "protein synthesis,penicillins 30S ribosome inhibitors protein synthesis,sulfonamides presence of vancomycin, shut down the normal pathway for bacterial cell wall synthesis, and produce a different type of cell wall."
        },
        {
            "id": "InternalMed_Harrison_11447",
            "title": "InternalMed_Harrison",
            "content": "Multiple essential components of bacterial cell structures and metabolism have been the targets of antibacterial agents used in clinical medicine, and the interaction of an agent with its target results in either inhibition of bacterial growth and replication (bacteriostatic effect) or bacterial killing (bactericidal effect). In general, targets have been chosen because they either do not exist in mammalian cells and physiology or are sufficiently different from their bacterial counterparts to allow selective bacterial targeting. Treatment with bacteriostatic agents is effective when the patient\u2019s host defenses are sufficient to contribute to eradication of the infecting pathogen. In patients with impaired host defenses (e.g., neutropenia) or infections at body sites with impaired or limited host defenses (e.g., meningitis and endocarditis), bactericidal agents are generally preferred."
        },
        {
            "id": "Pharmacology_Katzung_5647",
            "title": "Pharmacology_Katzung",
            "content": "Two major mechanisms of antimicrobial antagonism have been established: 1. Inhibition of cidal activity by static agents: Bacteriostatic agents such as tetracyclines and chloramphenicol can * Pneumocystis jiroveci is a fungal organism found in humans (P carinii infects animals) that responds to antiprotozoal drugs. See Chapter 52. antagonize the action of bactericidal cell wall-active agents because cell wall-active agents require that the bacteria be actively growing and dividing. 2. Induction of enzymatic inactivation: Some Gram-negative bacilli, including Enterobacter species, P aeruginosa, Serratia marcescens, and Citrobacter freundii, possess inducible \u03b2-lactamases. \u03b2-Lactam antibiotics such as imipenem, cefoxitin, and ampicillin are potent inducers of \u03b2-lactamase production. If an inducing agent is combined with an intrinsically active but hydrolyzable \u03b2-lactam such as piperacillin, antagonism may result."
        },
        {
            "id": "InternalMed_Harrison_11465",
            "title": "InternalMed_Harrison",
            "content": "Bacteria use a wide variety of mechanisms to block or circumvent the activity of antibacterial agents. Although myriad, these mechanisms can generally be grouped into three categories: (1) altered or bypass targets that exhibit reduced binding of the drug, (2) altered access of the drug to its target by reductions in uptake or increases in active efflux, and (3) a modification of the drug that reduces its activity. These mechanisms result from either mutations in bacterial chromosomal genes occurring spontaneously during bacterial DNA replication or the acquisition of new genes by DNA transfer from other bacteria or uptake of exogenous DNA. New genes are most often acquired on self-replicating plasmids or other DNA elements transferred from other bacteria. However, some bacteria, such as Streptococcus pneumoniae and Neisseria gonorrhoeae, can also take up fragments of environmental DNA from related species and recombine that DNA directly into their own chromosomes, a process called"
        },
        {
            "id": "InternalMed_Harrison_11885",
            "title": "InternalMed_Harrison",
            "content": "This synergistic effect can be explained, at least in part, by the increased penetration of the aminoglycoside into the bacterial cell, presumably as a result of cell wall alterations produced by the \u03b2-lactam (or glycopeptide). Nonetheless, attaining synergistic bactericidal activity in the treatment of severe enterococcal infections has become increasingly difficult because of the development of resistance to virtually all antibiotics available for this purpose."
        },
        {
            "id": "InternalMed_Harrison_11451",
            "title": "InternalMed_Harrison",
            "content": "bacitracin (topical) and fosfomycin These agents interrupt enzymatic steps in the production of peptidoglycan precursors in the cytoplasm. Inhibition of Protein Synthesis Most inhibitors of bacterial protein synthesis target bacterial ribosomes, whose difference from eukaryotic ribosomes allows selective antibacterial action. Some inhibitors bind to the 30S ribosomal subunit and others to the 50S subunit. Most protein synthesis\u2013inhibiting agents are bacteriostatic; aminoglycosides are an exception and are bactericidal."
        },
        {
            "id": "Pharmacology_Katzung_5145",
            "title": "Pharmacology_Katzung",
            "content": "Streptococci and enterococci are relatively resistant to gentamicin owing to failure of the drug to penetrate into the cell. However, gentamicin in combination with some penicillins or vancomycin produces a potent bactericidal effect, which in part is due to enhanced uptake of drug that occurs with inhibition of cell wall synthesis. Resistance to gentamicin rapidly emerges in staphylococci during monotherapy owing to selection of permeability mutants. Ribosomal resistance is rare. Among Gram-negative bacteria, resistance is most commonly due to plasmid-encoded aminoglycoside-modifying enzymes. Gram-negative bacteria that are gentamicin-resistant usually are susceptible to amikacin, which is much more resistant to modifying enzyme activity. The enterococcal enzyme that modifies gentamicin is a bifunctional enzyme that also inactivates amikacin, netilmicin, and tobramycin but not streptomycin; the latter is modified by a different enzyme. This is why some gentamicin-resistant"
        },
        {
            "id": "Cell_Biology_Alberts_6520",
            "title": "Cell_Biology_Alberts",
            "content": "23\u201315 The majority of antibiotics used in the clinic are made as natural products by bacteria. Why do you suppose bacteria make the very agents we use to kill them? 23\u201316 In the early days of penicillin research, it was discovered that bacteria in the air could destroy the penicillin, a big problem for large-scale production of the drug. How do you suppose this occurs? 23\u201317 When the Oxford team of Ernst Chain and Norman Heatley had laboriously collected their first two grams of penicillin (probably no more than 2% pure!), Chain injected two normal mice with 1 g each of this preparation, and waited to see what would happen. The mice survived with no apparent ill effects. Their boss, Howard Florey, was furious at what he saw as a waste of good antibiotic. Why was this experiment important? Cossart P, Boquet P, Normark S & Rappuoli R (eds) (2005) Cellular Microbiology, 2nd ed. Washington, DC: ASM Press."
        },
        {
            "id": "Surgery_Schwartz_1244",
            "title": "Surgery_Schwartz",
            "content": "selection pres-sure will drive proliferation of more organisms resistant to that antibiotic. This acquired antibiotic resistance can be mutational, leading to changes in the chromosomal makeup of the microbe, or it can be extrachromosomal, induced by transfer of exog-enous genetic material in the form of a plasmid or transposon. In either case, cellular mechanisms of resistance that develop include target site modification, changes in bacterial permeabil-ity or antibiotic uptake, activation of drug efflux systems, and drug deactivation. Given that millions of kilograms of antibiot-ics are used annually in people, in agriculture, and for animal use, environmental selection pressures are high, and antibiotic resistance has now been described in all classes of antibiotics in common use. Antibiotic resistance comes at a high cost, with a significant increase in mortality associated with infection from resistant organisms, and an economic cost of billions of dollars per year.There are"
        },
        {
            "id": "Pharmacology_Katzung_5051",
            "title": "Pharmacology_Katzung",
            "content": "The drugs described in this chapter inhibit bacterial protein synthesis by binding to and interfering with ribosomes. Most are bacteriostatic, but a few are bactericidal against certain organisms. Tetracycline and macrolide resistance is common. Except for tigecycline and the streptogramins, these antibiotics may be administered orally. All of the tetracyclines have the basic structure shown at right: *There is no OH at position 6 on methacycline and doxycycline. Free tetracyclines are crystalline amphoteric substances of low solubility. They are available as hydrochlorides, which are more soluble. Such solutions are acidic and fairly stable. Tetracyclines chelate divalent metal ions, which can interfere with their absorption and activity. Tigecycline is a glycylcycline and a semisynthetic derivative of minocycline. Mechanism of Action & Antimicrobial Activity"
        },
        {
            "id": "Pharmacology_Katzung_4953",
            "title": "Pharmacology_Katzung",
            "content": "Resistance due to impaired penetration of antibiotic occurs only in Gram-negative species because of the impermeable outer membrane of their cell wall, which is absent in Gram-positive bacteria. Beta-lactam antibiotics cross the outer membrane and enter Gram-negative organisms via outer membrane protein channels called porins. Absence of the proper channel or down-regulation of its production can greatly impair drug entry into the cell. Poor penetration alone is usually not sufficient to confer resistance because enough antibiotic eventually enters the cell to inhibit growth. However, this barrier can become important in the presence of a \u03b2-lactamase, even a relatively inefficient one, as long as it can hydrolyze drug faster than it enters the cell. Gram-negative organisms also may produce an efflux pump, which consists of cytoplasmic and periplasmic protein components that efficiently transport some \u03b2-lactam antibiotics from the periplasm back across the cell wall outer membrane."
        },
        {
            "id": "Cell_Biology_Alberts_6378",
            "title": "Cell_Biology_Alberts",
            "content": "Although bacteria generally lack internal membranes, they are highly sophisticated cells whose organization and behaviors have attracted the attention of many scientists. Bacteria are classified broadly by their shape\u2014as rods, spheres (cocci), or spirals (Figure 23\u20133A)\u2014 as well as by their so-called Gram-staining properties, which reflect differences in the structure of the bacterial cell wall. Gram-positive bacteria have a thick layer of peptidoglycan cell wall outside their inner (plasma) membrane (Figure 23\u20133B), whereas Gram-negative bacteria have a thinner peptidoglycan cell wall. In both cases, the cell wall protects against lysis by osmotic swelling, and it is a target of host antibacterial proteins such as lysozyme and antibiotics such as penicillin. Gram-negative bacteria are also covered outside the cell wall by an outer membrane containing lipopolysaccharide (LPS) (Figure 23\u20133C). Both peptidoglycan and LPS are unique to bacteria and are recognized as pathogen-associated"
        },
        {
            "id": "Histology_Ross_249",
            "title": "Histology_Ross",
            "content": "polysome. A polysome attached to the cytoplasmic surface of the rER can translate a single mRNA molecule and simultaneously produce many copies of a particular protein. In contrast, free ribosomes reside within the cytoplasm. They are not associated with any intracellular membranes and are structurally and functionally identical to polysomes of the rER. The differences between the structure of prokaryotic (bacterial) and eukaryotic ribosomes were exploited by researchers, who discovered chemical compounds (antibiotics) that bind to bacterial ribosomes, thereby destroying a bacterial infection without harming the cells of the infected individual. Several types of antibiotics, such as aminoglycosides (streptomycin), macrolides (erythromycin), lincosamides (clindamycin), tetracyclines, and chloramphenicol inhibit protein synthesis by binding to different portions of bacterial ribosomes. Signal peptides direct the post-translational transport of a protein."
        },
        {
            "id": "Pharmacology_Katzung_5630",
            "title": "Pharmacology_Katzung",
            "content": "Proposed mechanisms include (1) slow recovery after reversible nonlethal damage to cell structures; (2) persistence of the drug at a binding site or within the periplasmic space; and (3) the need to synthesize new enzymes before growth can resume. Most antimicrobials possess significant in vitro PAEs (\u22651.5 hours) against susceptible Gram-positive cocci (Table 51\u20134). Antimicrobials TABLE 51\u20134 Antibacterial agents with in vitro postantibiotic effects \u22651.5 hours. with significant PAEs against susceptible Gram-negative bacilli are limited to carbapenems and agents that inhibit protein or DNA synthesis."
        },
        {
            "id": "Surgery_Schwartz_2284",
            "title": "Surgery_Schwartz",
            "content": "increase with further increases in drug dose.Anticancer AgentsAlkylating Agents. Alkylating agents are cell-cycle\u2013 nonspecific agents, that is, they are able to kill cells in any phase of the cell cycle. They act by cross-linking the two strands of the DNA helix or by causing other direct damage to the DNA. The damage to the DNA prevents cell division and, if severe enough, leads to apoptosis. The alkylating agents are composed of three main subgroups: classic alkylators, nitrosoureas, and miscellaneous DNA-binding agents (Table 10-10).Antitumor Antibiotics. Antitumor antibiotics are the prod-ucts of fermentation of microbial organisms. Like the alkylat-ing agents, these agents are cell-cycle nonspecific. Antitumor antibiotics damage the cell by interfering with DNA or RNA synthesis, although the exact mechanism of action may differ by agent.Antimetabolites. Antimetabolites are generally cell-cycle\u2013specific agents that have their major activity during the S phase of the cell cycle and"
        },
        {
            "id": "Pharmacology_Katzung_5645",
            "title": "Pharmacology_Katzung",
            "content": "2. Inhibition of enzymatic inactivation: Enzymatic inactivation of \u03b2-lactam antibiotics is a major mechanism of antibiotic resistance. Inhibition of \u03b2 lactamase by \u03b2-lactamase inhibitor drugs (eg, sulbactam) results in synergism. 3. Enhancement of antimicrobial agent uptake: Penicillins and other cell wall-active agents can increase the uptake of aminoglycosides by a number of bacteria, including staphylococci, enterococci, streptococci, and P aeruginosa. Enterococci are thought to be intrinsically resistant to aminoglycosides because of permeability barriers. Similarly, amphotericin B is thought to enhance the uptake of flucytosine by fungi. Mechanisms of Antagonistic Action"
        },
        {
            "id": "InternalMed_Harrison_11448",
            "title": "InternalMed_Harrison",
            "content": "Inhibition of Cell Wall Synthesis The bacterial cell wall, which is external to the cytoplasmic membrane and has no counterpart in mammalian cells, protects bacterial cells from lysis under low osmotic conditions. The cell wall is a cross-linked peptidoglycan composed of a polymer of alternating units of N-acetylglucosamine (NAG) and N-acetylmuramic acid (NAM), four-amino-acid stem peptides linked to each NAM, and a peptide cross-bridge that links adjacent stem peptides to form a net-like structure. Several steps in peptidoglycan synthesis are targets of antibacterial agents. Inhibition of cell wall synthesis generally results in a bactericidal effect that is linked to cell lysis. This effect results not only from the blocking of new cell-wall formation but from the uninhibited action of cell wall\u2013remodeling enzymes called autolysins, which cleave peptidoglycan as part of normal cell-wall growth."
        },
        {
            "id": "Gynecology_Novak_3747",
            "title": "Gynecology_Novak",
            "content": "Patients with valvular abnormalities are subdivided by the American Heart Association into risk groups for the development of subacute bacterial endocarditis following surgery. Patients in the highest risk groups should receive prophylactic antibiotics immediately preoperatively to prevent subacute bacterial endocarditis (Table 22.8). As defined by the American Heart Association, only patients with prosthetic cardiac valves, congenital heart disease, and cardiac transplantation who develop cardiac valvulopathy should receive perioperative endocarditis prophylaxis (76). All other patients do not require antibiotics for subacute bacterial endocarditis prophylaxis. Routine prophylaxis for GI or GU procedures is not recommended. Only in cases of a known infection of the GI or GU tract should antibiotics coverage for enterococcus with amoxicillin or ampicillin or vancomycin be provided."
        },
        {
            "id": "Cell_Biology_Alberts_6506",
            "title": "Cell_Biology_Alberts",
            "content": "ejects the drug from the bacterial cytoplasm (using energy derived from either ATP hydrolysis or the electrochemical gradient across the bacterial plasma membrane) will survive and proliferate. Some efflux pumps, such as the TetR efflux pump, are specific for a single drug (in this case, tetracycline), whereas others, called multidrug resistance (MDR) efflux pumps, are capable of exporting a wide variety of structurally dissimilar drugs. Upregulation of an MDR pump can render a bacterium resistant to a very large number of different antibiotics in a single step."
        }
    ],
    "scores": [
        0.03875975198598027,
        0.03832208651714867,
        0.033716517269148844,
        0.029034690799396683,
        0.028941285251964863,
        0.02781325695796249,
        0.027019383090028833,
        0.02622059076020481,
        0.02575253999051811,
        0.025459263605514187,
        0.025161111641232477,
        0.02490744281871314,
        0.02347570729923671,
        0.023434377081945366,
        0.023069425701004648,
        0.02207411608999811,
        0.022064986762013163,
        0.020697764171801615,
        0.020584037016046323,
        0.019725744107808446,
        0.019327731092436976,
        0.018995459923729967,
        0.018978233495232956,
        0.018162393162393164,
        0.01804716021305883,
        0.017897015265436318,
        0.017412370353546824,
        0.01721981014055486,
        0.016807909604519774,
        0.01625538582060321,
        0.01623521891978268,
        0.01592157842157842
    ],
    "execution_time": 34.67478537559509
}